MIC values of voriconazole are predictive of treatment results in murine infections by aspergillus terreus species complex

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1532-1534

  Salas, Valentina ^a   Javier Pastor, F ^a   Sutton, Deanna A ^c   Calvo, Enrique ^a   Mayayo, Emilio ^b   Fothergill, Annette W ^c   Rinaldi, Michael G ^c   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS TERREUS; BLOOD SAMPLING; BRAIN TISSUE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; MALE; MANNANS; MICE; MICROBIAL SENSITIVITY TESTS; PROGNOSIS; PYRIMIDINES; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 84874041796     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01436-12     Document Type: Article

References (17)

1. Chandrasekar PH, Cutright J, Manuvathu E. 2000. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J. Antimicrob. Chemother. 45:673- 676.
2. Lass-Flörl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, Freund M, Kropshofer G, Dierich MP, Nachbaur D. 2005. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br. J. Haematol. 131:201-207.
3. Walsh TJ, Anaissie E, Denning DW, Herbrecht R, Kontoyiannis D, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
4. Howard SJ, Cerar D, Anderson J, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. 2009.Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068 -1076.
5. Verweij PE, Howard SJ, Melchers WJ, Denning DW. 2009. Azoleresistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
6. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaller MA, Rinaldi MG, Cantón E, Turnidge J. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
7. Pfaller MA, Diekema DJMA, Ghannoum Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinell-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostroski-Zeichner L, Sheehan DJ, Walsh TJ, Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee. 2009. Wild type distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standard Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
8. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. Document M38-A2. CLSI, Wayne, PA.
9. Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A, Heep M, Denning DW. 2006. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J. Antimicrob. Chemother. 58: 1198-1207.
10. Sugar AM, Liu XP. 2000. Effect of grapefruit juice on serum voriconazole concentration in the mouse. Med. Mycol. 38:209 -212.
11. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. 2009. Efficacy of isavuconazole, voriconazole and fluconazole in temporally neutropenic murine model of disseminated Candida tropicalis and Candida krusei. J. Antimicrob. Chemother. 63:161-166.
12. Rodríguez MM, Calvo E, Serena C, Mariné M, Pastor FJ, Guarro J. 2009. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob. Agents Chemother. 53:2153-2155.
13. Sionov E, Mendlovic S, Segal E. 2005. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J. Antimicrob. Chemother. 56:594 -597.
14. Guarro J. 2011. Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi. J. Antimicrob. Chemother. 66:1447-1466.
15. Manavathu EK, Cutright JL, Chandrasekar PH. 1998. Organismdependent fungicidal activities. Antimicrob. Agents Chemother. 42: 3018-3021.
16. Salas V, Pastor FJ, Rodríguez MM, Calvo E, Mayayo E, Guarro J. 2011. In vitro activity and in vivo efficacy of posaconazole in the treatment of murine infections by different isolates of the Aspergillus terreus complex. Antimicrob. Agents Chemother. 55:676-679.
17. Pfaller MA, Boyken R, Hollis J, Kroeger J, Messer S, Tendolkar S, Diekema D. 2011. Use of epidemiological cuttof values to examine 9 year trends in susceptibility of Aspergillus species to triazoles. J. Clin. Microbiol. 49:586 -590.